Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,573 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597753
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin Alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
89
States / cities
Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 25, 2026, 6:20 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis

NCT02434757
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Ronald J. Rapoport, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fall River, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 2 Interventional

Infliximab for the Treatment of Early Rheumatoid Arthritis

NCT00006292
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 6:20 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Chewing Gum on Bowel Preparation in Patients Undergoing Colonoscopy

NCT07320989
View directory record Official record
Conditions
Colon Cancer Screening
Interventions
Chewing Sugar-Free Gum During Bowel Preparation, Standard Bowel Prep (2L PEG-ELP), Standard Bowel Prep
Behavioral · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
45 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 25, 2026, 6:20 PM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

NCT04032158
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 25, 2026, 6:20 PM EDT
Withdrawn Phase 2 Interventional

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

NCT04482933
View directory record Official record
Conditions
Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma
Interventions
Biological G207
Biological
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Aurora, Colorado • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

NCT02891226
View directory record Official record
Conditions
Crohn's Disease
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
44
States / cities
Huntsville, Alabama • Tucson, Arizona • Garden Grove, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 4 Interventional Results available

Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial

NCT05322252
View directory record Official record
Conditions
Abortion, Second Trimester, PPROM, Rupture, Spontaneous, Fetal Demise, Fetal Death, Fetal Demise From Miscarriage, Fetal Death Before 22 Weeks With Retention of Dead Fetus, Pregnancy Loss, Pregnancy Complications
Interventions
Mifepristone, Misoprostol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 25, 2026, 6:20 PM EDT
Withdrawn Phase 2 Interventional

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

NCT00081055
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
autologous expanded mesenchymal stem cells OTI-010, busulfan, cyclophosphamide, cyclosporine, methotrexate, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 25, 2026, 6:20 PM EDT
Terminated Not applicable Interventional Results available

Outpatient Foley Catheter Compared to Usual Inpatient Care for Labor Induction

NCT02546193
View directory record Official record
Conditions
Pregnancy
Interventions
Foley catheter, Misoprostol
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

NCT01969058
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Isotretinoin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Trial of Oral Misoprostol for Labor Augmentation

NCT00906347
View directory record Official record
Conditions
Labor Augmentation
Interventions
Misoprostol, Oxytocin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Oct 25, 2026, 6:20 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

NCT04115748
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Filgotinib, Adalimumab, Placebo to match filgotinib, Placebo to match adalimumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
Covina, California • Brandon, Florida • DeBary, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Oct 25, 2026, 6:20 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

NCT03594175
View directory record Official record
Conditions
Catheter Occlusion, Thrombosis
Interventions
CUSA-081, Placebo, Alteplase
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 3 Interventional

A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence

NCT06387394
View directory record Official record
Conditions
Masseter Muscle Prominence
Interventions
BOTOX, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

NCT01162122
View directory record Official record
Conditions
Influenza
Interventions
MF59 adjuvanted trivalent subunit influenza vaccine (aTIV), Non-adjuvanted trivalent subunit influenza vaccine (TIV)
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
65 Years and older
Enrollment
7,109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
Phoenix, Arizona • DeLand, Florida • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

NCT02986854
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 55 Years
Enrollment
704 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 25, 2026, 6:20 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Psychoeducation Intervention for Caregivers of Patients With Bipolar Disorder

NCT02446509
View directory record Official record
Conditions
Bipolar Disorder Family Members
Interventions
Psychoeducation, Psychoeducation - Delayed
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 3 Interventional

Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

NCT00028938
View directory record Official record
Conditions
Lung Cancer
Interventions
epoetin alfa, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of EITC on Biological Markers of Aging, Health and Mortality

NCT03226548
View directory record Official record
Conditions
Poverty, Tax Policy
Interventions
Paycheck Plus
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 4 Interventional Results available

Misoprostol Dosing in BMI Greater Than 30

NCT05262738
View directory record Official record
Conditions
Pregnancy Related, Obesity, Labor Onset and Length Abnormalities
Interventions
50 Micrograms Vaginal Misoprostol (Intervention), 25 Micrograms Vaginal Misoprostol (Control)
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Early Phase 1 Interventional

Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy

NCT01306838
View directory record Official record
Conditions
Short Bowel Syndrome, Necrotizing Enterocolitis, Small Intestine Perforation
Interventions
MicroLipid and fish oil, Routine care
Dietary Supplement · Other
Lead sponsor
Wake Forest University
Other
Eligibility
1 Day to 60 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 25, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Results available

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

NCT01258387
View directory record Official record
Conditions
Heart Failure
Interventions
Glial growth factor 2/ Neuregulin 1β3, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 25, 2026, 6:20 PM EDT